In stage II-III CRC, MMP-9 cleavable PNPs (MMP9-PNPs) target KRASG12D mutations by delivering mRNA vaccines specifically to MMP-9 rich invasive tumor regions (Hong et al., 2025). This evidence concerns the gene MMP9 and colorectal carcinoma.